Literature DB >> 11792830

Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.

Carmen Martinez1, Catalina Abad, Mario Delgado, Alicia Arranz, Maria G Juarranz, Nieves Rodriguez-Henche, Philippe Brabet, Javier Leceta, Rosa P Gomariz.   

Abstract

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are two mediators synthesized by immune cells, specially under inflammatory and antigen stimulation conditions. Reports have shown that neuropeptides attenuate the deleterious consequences of septic shock both by down-regulating the production of proinflammatory mediators and by stimulating the production of anti-inflammatory cytokines by activated macrophages. In this study, we used a knockout for the PACAP receptor (PAC1(-/-)) to demonstrate an important protective role for PAC1 receptor in endotoxic shock. Moreover, our results indicate that PAC1 receptor acts in vivo as an anti-inflammatory receptor, at least in part, by attenuating lipopolysaccharide (LPS)-induced production of proinflammatory IL-6, which appears to be the main cytokine regulating the expression of the majority of the acute phase protein genes, which are an important deleterious component of septic shock. Besides, our findings point to endogenously produced VIP and PACAP as participants of the natural anti-inflammatory machinery. Because VIP and PACAP are two attractive candidates for the development of therapies against acute and chronic inflammatory diseases, septic shock, and autoimmune diseases, this paper represents a contribution to the understanding of the mechanism of action of these anti-inflammatory agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792830      PMCID: PMC117428          DOI: 10.1073/pnas.012367999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  The acute-phase response.

Authors:  B H Pannen; J L Robotham
Journal:  New Horiz       Date:  1995-05

2.  Expression of vasoactive intestinal peptide binding sites in rat peritoneal macrophages is stimulated by inflammatory stimulus.

Authors:  J J Segura; J M Guerrero; D Pozo; J R Calvo
Journal:  J Neuroimmunol       Date:  1996-01       Impact factor: 3.478

3.  Differential signal transduction by five splice variants of the PACAP receptor.

Authors:  D Spengler; C Waeber; C Pantaloni; F Holsboer; J Bockaert; P H Seeburg; L Journot
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

4.  Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation.

Authors:  C Pantaloni; P Brabet; B Bilanges; A Dumuis; S Houssami; D Spengler; J Bockaert; L Journot
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

5.  Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor.

Authors:  M Klouche; S Bhakdi; M Hemmes; S Rose-John
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

6.  Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome.

Authors:  L C Casey; R A Balk; R C Bone
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

Review 7.  Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system.

Authors:  J Leceta; C Martínez; M Delgado; E Garrido; R P Gomariz
Journal:  Adv Neuroimmunol       Date:  1996

8.  Cyclic nucleotides and vasoactive intestinal peptide production in a rabbit model of Escherichia coli septicemia.

Authors:  C W Broner; M S O'Dorisio; R B Rosenberg; T M O'Dorisio
Journal:  Am J Med Sci       Date:  1995-05       Impact factor: 2.378

9.  Demonstration of immunoreactive vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus.

Authors:  R P Gomariz; M J Lorenzo; L Cacicedo; A Vicente; A G Zapata
Journal:  Brain Behav Immun       Date:  1990-06       Impact factor: 7.217

10.  Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats.

Authors:  R Lundblad; P Ekstrøm; K E Giercksky
Journal:  Shock       Date:  1995-03       Impact factor: 3.454

View more
  39 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

Review 2.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Biological and structural analysis of truncated analogs of PACAP27.

Authors:  Steve Bourgault; David Vaudry; Laure Guilhaudis; Emilie Raoult; Alain Couvineau; Marc Laburthe; Isabelle Ségalas-Milazzo; Hubert Vaudry; Alain Fournier
Journal:  J Mol Neurosci       Date:  2008-05-13       Impact factor: 3.444

4.  PACAP is a pathogen-inducible resident antimicrobial neuropeptide affording rapid and contextual molecular host defense of the brain.

Authors:  Ernest Y Lee; Liana C Chan; Huiyuan Wang; Juelline Lieng; Mandy Hung; Yashes Srinivasan; Jennifer Wang; James A Waschek; Andrew L Ferguson; Kuo-Fen Lee; Nannette Y Yount; Michael R Yeaman; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-05       Impact factor: 11.205

Review 5.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

6.  Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice.

Authors:  H D Lauenstein; D Quarcoo; L Plappert; C Schleh; M Nassimi; C Pilzner; S Rochlitzer; P Brabet; T Welte; H G Hoymann; N Krug; M Müller; E A Lerner; A Braun; D A Groneberg
Journal:  Clin Exp Allergy       Date:  2010-11-09       Impact factor: 5.018

7.  Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor.

Authors:  Hirokazu Ohtaki; Atsushi Satoh; Tomoya Nakamachi; Sachiko Yofu; Kenji Dohi; Hiroyoshi Mori; Kenji Ohara; Kazuyuki Miyamoto; Hitoshi Hashimoto; Norihito Shintani; Akemichi Baba; Masaji Matsunaga; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2010-04-13       Impact factor: 3.444

Review 8.  Parasympathetic innervation of vertebrobasilar arteries: is this a potential clinical target?

Authors:  Eva V L Roloff; Ana M Tomiak-Baquero; Sergey Kasparov; Julian F R Paton
Journal:  J Physiol       Date:  2016-10-05       Impact factor: 5.182

9.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Yoichi Aizawa; Atsushi Takaki; Kei Hodoyama; Sachiko Yofu; Hitoshi Hashimoto; Norihito Shintani; Akemichi Baba; Manfred Kopf; Yoichiro Iwakura; Kouhei Matsuda; Akira Arimura; Seiji Shioda
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

10.  Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.

Authors:  Alejo Chorny; Mario Delgado
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.